Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

beta-Thalassemia 1Supratentorial Brain Tumor Surgery 1Post-operative Residual Curarization 1Neoplasms 1Hepatoblastoma 1Brain Neoplasms 1

Interventions

Exercise 19Drug Therapy 18pembrolizumab 13Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Paclitaxel 9Dexamethasone 9Nivolumab 8Standard of Care 7Oxaliplatin 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Control Groups 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasms × Sugammadex × Clear all
NCT03728543 2018-11-02

the Efficacy and Safety of Sugammadex in Children 0-2 Years Old

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Unknown
62 enrolled
Gastrointestinal

Neoplasms, beta-Thalassemia, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡